Abstract:Objective: To explore the clinical features and prognosis of patients with primary central nervous system lymphoma（PCNSL）. Methods: A retrospective analysis was performed on the relationship between clinical features, treatment regimen and prognosis in 46 newly diagnosed patients with primary central nervous system lymphoma who were diagnosed and treated in The Second Hospital of Lanzhou University from January 2015 to September 2022. Fisher's exact probability method was used to analyze the differences in clinical data of different subgroups. Kaplan-Meier survival curve was used to analyze the overall survival rate and progression-free survival rate of patients with different treatments, and the factors influencing survival were analyzed. Results: Among 46 patients with PCNSL, which pathological type were diffuse large B-cell lymphoma（DLBCL）. There were 26(56.5%) cases of male and 20(43.5%) of female, with a median age of 54(17-71) years. In Hans subtypes, 14 cases (30.4%) of GCB subtype, 32 cases (69.6%) of non-GCB subtype. 32 cases (69.6%) of Ki-67≥80%. Among 36 patients who completed at least 2 cycles of treatment with follow-up data, the efficacy evaluation was as follows: overall response rate(ORR) was 63.9%, complete response(CR) rate was 47.2%, 17 cases of CR, 6 cases of PR. The 1-year progression-free survival rate and 1-year overall survival rate was 73.6% and 84.9%, respectively. The 2-year progression-free survival rate and 2-year overall survival rate was 52.2% and 68.9%, respectively. The ORR and CR rate of 17 patients treated with RMT regimen was 76.5% and 52.9% (9 cases CR and 4 cases PR), respectively. Univariate analysis of 3 groups of patients treated with RMT regimen, RM-BTKi regimen, and RM-TT regimen as first-line treament showed that deep brain infiltration was associated with adverse PFS(P =0.032), and treatment regimen was associated with adverse OS in PCNSL patients（P =0.025）. Conclusion: Different treatment modalities were independent prognosis predictors for OS, the deep brain infiltration of PCNSL is a poor predictive factor for PFS. Patients with relapse/refractory (R/R) PCNSL have a longer overall survival time because to the novel medication BTKi. They have strong toleration and therapeutic potential as a first-line therapy for high-risk patients.

Central nervous system lymphoma and its significance ZHENG Wen, LIN Ning-jing,

Central nervous system lymphoma and its significance]

Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre.

The Clinical Features and Survival Analysis of Primary Central Nervous System Lymphoma

A Retrospective Study of 40 Cases of Pathologically Established Primary Central Nervous System Lymphoma

Diagnosis and treatment of acute leukemia with central nervous system infiltration

Clinical features analysis on primary central nervous system lymphoma

Cerebrospinal Fluid IL-6 and IL-10 As Promising Diagnostic and Therapeutic Prognostic Biomarkers for Secondary Central Nervous System Lymphoma

[Clinical Features and Prognostic of Patients with Primary Central Nervous System Lymphoma]

Survival outcomes and treatment experience of 124 patients with primary central nervous system lymphoma

Primary central nervous system lymphoma: a series report and literature review

Clinical,image and pathological features of 71 cases with primary central nervous system lymphoma

Primary central nervous system lymphoma in China: a single-center retrospective analysis of 167 cases

Primary Central Nervous System Lymphoma, Treatment Outcomes - 10 Year Experience. Single Center Study

Advances in relevant prognostic factors of primary central nervous system lymphoma

Prognostic Value of Clinical Characteristics and Immunophenotypic Biomarkers in 115 Patients with Primary Central Nervous System Lymphoma.

Epidemiologic Characteristics, Prognostic Factors, and Treatment Outcomes in Primary Central Nervous System Lymphoma: A SEER-Based Study

[Clinical Characteristics and Prognosis of 21 Cases of Acute Lymphoblastic Leukemia with Central Nervous System Leukemia]

Central Nervous System Involvement in Patients with Diffuse Large B Cell Lymphoma: Analysis of the Risk Factors and Prognostic from a Single-Center Retrospective Cohort Study

Prognostic significance of CNSL at diagnosis of childhood B-cell acute lymphoblastic leukemia: A report from the South China Children’s Leukemia Group

Advances in the Diagnosis and Treatment of Primary Central Nervous System Lymphoma